Drugs Made In America Acquisition (DMAA) Other Working Capital Changes (2025)
Drugs Made In America Acquisition's (DMAA) quarterly Other Working Capital Changes came in at -$21425.0 in Q4 2025, little changed quarter-over-quarter from -$21425.0 in Q3 2025.
Powered by 
Analysis
Drugs Made In America Acquisition (DMAA) Other Working Capital Changes (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAA) has reported Other Working Capital Changes for 1 consecutive years, with -$21425.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Working Capital Changes changed N/A year-over-year to -$21425.0; the trailing twelve-month figure through Dec 2025 stood at $6054.0 (changed N/A YoY), and the FY2025 full-year result was $6054.0, changed N/A from the prior year.
- Other Working Capital Changes was little changed at -$21425.0 in Q4 2025 per DMAA's latest filing, from -$21425.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $70096.0 in Q1 2025 and bottomed at -$21425.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Blackstone | 102.43 Bn | 104.87 Bn | - |
| 2 | Kkr | 96.71 Bn | -180.36 Bn | - |
| 3 | Brookfield Asset Management | 80.84 Bn | 80.57 Bn | - |
| 4 | Apollo Global Management | 76.99 Bn | 72.09 Bn | 10.54 Bn |
| 5 | Wheaton Precious Metals | 70.37 Bn | 70.27 Bn | 687.86 Mn |
| 6 | Franco Nevada | 51.31 Bn | 49.77 Bn | 451.00 Mn |
| 7 | Ares Management | 50.50 Bn | 55.42 Bn | - |
| 8 | Brookfield | 37.98 Bn | 7.42 Bn | 19.38 Bn |
| 9 | Tpg | 20.58 Bn | 22.14 Bn | - |
| 10 | Drugs Made In America Acquisition | 332.47 Mn | 332.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -21,425.00 |
| Dec 31, 2025 | -21,425.00 |
| Sep 30, 2025 | -21,425.00 |
| Sep 30, 2025 | -21,425.00 |
| Jun 30, 2025 | -21,192.00 |
| Jun 30, 2025 | -21,192.00 |
| Mar 31, 2025 | 70,096.00 |
| Mar 31, 2025 | 70,096.00 |